Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto, H., Sakai, N., Ohte, S., Sato, T., Sekimata, K., Matsumoto, T., Nakamura, K., Watanabe, H., Mishima-Tsumagari, C., Tanaka, A., Hashizume, Y., Honma, T., Katagiri, T., Miyazono, K., Tomoda, H., Shirouzu, M., Koyama, H.(2021) Bioorg Med Chem Lett 38: 127858-127858
- PubMed: 33609658 
- DOI: https://doi.org/10.1016/j.bmcl.2021.127858
- Primary Citation of Related Structures:  
7C3G - PubMed Abstract: 
Mutant activin receptor-like kinase-2 (ALK2) is associated with the pathogenesis of fibrodysplasia ossificans progressiva, making it an attractive target for therapeutic intervention. We synthesized a new series of bicyclic pyrazoles and evaluated their mutant ALK2 enzyme inhibitory activities, leading to the identification of 8 as the most potent inhibitor. This compound showed moderate microsomal metabolic stability and human ether-a-go-go related gene (hERG) safety. In C2C12 cells carrying mutant ALK2 (R206H), 8 efficiently inhibited the bone morphogenetic protein (BMP)-induced alkaline phosphatase activity.
Organizational Affiliation: 
Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.